SQ109是一种开发中的抗分枝杆菌药物,靶点为分枝杆菌的MMPL3蛋白(mycobacterial membrane protein large 3,分枝杆菌膜蛋白3)。[1][2]
参考文献
- ^ Jia, L; Tomaszewski, JE; Hanrahan, C; Coward, L; Noker, P; Gorman, G; Nikonenko, B; Protopopova, M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.. British journal of pharmacology. 2005-01, 144 (1): 80–7. PMID 15644871. doi:10.1038/sj.bjp.0705984.
- ^ Meng, Q; Luo, H; Liu, Y; Li, W; Zhang, W; Yao, Q. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.. Bioorganic & medicinal chemistry letters. 2009-05-15, 19 (10): 2808–10. PMID 19362471. doi:10.1016/j.bmcl.2009.03.091.
外部链接